Familial isolated GH deficiency type II (IGHD II) is caused, in some cases, by heterogeneous IVS3 mutations that affect GH mRNA splicing. We report here our finding an A3 G transition of the fifth base of exon 3 (E3؉ 5 A3 G) in affected individuals from an IGHD II family. This mutation disrupts a (GAA) n exon splice enhancer (ESE) motif immediately following the weak IVS2 3 splice site. The mutation also destroys an MboII site used to demonstrate heterozygosity in all affected family members. To determine the effect of ESE mutations on GH mRNA processing, GH 3 cells were transfected with expression constructs containing the normal ESE, ؉5 A3 G, or other ESE mutations, and cDNAs derived from the resulting GH mRNAs were sequenced. All ESE mutations studied reduced activation of the IVS2 3 splice site and caused either partial E3 G H DEFICIENCY (GHD) is a disorder that has been estimated to occur in 1 of 4,000 to 1 of 10,000 births, with 5-30% of patients having affected relatives (1-3). An autosomal dominant form of GHD (IGHD II) is caused by mutations in intron 3 (IVS3) of the GH 1 gene. One such mutation is a sixth base transition (ϩ6 T3 C) of the IVS3 5Ј splice site that causes aberrant GH mRNA splicing, resulting in deletion of exon 3 (E3) (4, 5) and loss of amino acids 32-71 from the mature 22-kDa GH protein, which produces a truncated product corresponding to the 17.5-kDa isoform of GH (6). IVS3 mutations ϩ1 G3 C (5, 7), ϩ1 G3 A (5, 8, 9), and ϩ5 G3 A (9, 10) have also been reported to cause IGHD II and have the same effects on splicing as those described above. Additional IVS3 mutations ϩ28 G3 A (5, 11) and del ϩ28 -45 (11) have been found to cause IGHD II. Analyses of these mutations led to the localization of an intron splice enhancer within IVS3 of the GH gene (12).
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G H DEFICIENCY (GHD) is a disorder that has been
estimated to occur in 1 of 4,000 to 1 of 10,000 births, with 5-30% of patients having affected relatives (1) (2) (3) . An autosomal dominant form of GHD (IGHD II) is caused by mutations in intron 3 (IVS3) of the GH 1 gene. One such mutation is a sixth base transition (ϩ6 T3 C) of the IVS3 5Ј splice site that causes aberrant GH mRNA splicing, resulting in deletion of exon 3 (E3) (4, 5) and loss of amino acids 32-71 from the mature 22-kDa GH protein, which produces a truncated product corresponding to the 17.5-kDa isoform of GH (6) . IVS3 mutations ϩ1 G3 C (5, 7), ϩ1 G3 A (5, 8, 9) , and ϩ5 G3 A (9, 10) have also been reported to cause IGHD II and have the same effects on splicing as those described above. Additional IVS3 mutations ϩ28 G3 A (5, 11) and del ϩ28 -45 (11) have been found to cause IGHD II. Analyses of these mutations led to the localization of an intron splice enhancer within IVS3 of the GH gene (12) .
We report here our finding an A3 G transition of the fifth base (ϩ5 A3 G) in E3 in affected individuals from a family with IGHD II and the implication of this finding. This mutation is located in an exon splice enhancer (ESE) motif (13) that immediately follows the weak 3Ј splice site of IVS2. In transient expression assays the natural E3ϩ 5 A3 G mutation and a variety of additional ESE point mutations all cause reduced activation of the IVS2 3Ј splice site, resulting in aberrant GH mRNA splicing. This aberrant splicing causes deletion of the first 15 nucleotides of E3 and loss of amino acids 32-46 of the GH product as a result of the activation of a cryptic 3Ј splice site located at base 45 of E3 (E3ϩ 45). The truncated product corresponds to the 20-kDa isoform of GH (6) . Aberrant splicing also results in the complete skipping of E3 and loss of amino acids 32-71 of the mature GH product as described above in the case of the IVS3 mutations. These data indicate that the ϩ5 A3 G mutation perturbs an ESE in E3 and causes IGHD II. Our findings show that aberrant GH pre-mRNA splicing is caused by point mutations of an ESE, demonstrating the importance of normal ESE function for the production of the mature 22-kDa GH protein.
Subjects and Methods Subjects
We studied DNAs from members of a Swiss IGHD II family whose pedigree and clinical characteristics (14, 15) are shown in Fig. 1 and Table  1 , respectively (written informed consent was obtained from all family members). There is no known history of consanguinity. IGF-I and IGFbinding protein-3 were measured in family members IV1 and IV2 and ranged from Ϫ3.2 to Ϫ2.8 sd score and from Ϫ2.8 to Ϫ2.4 sd score, respectively.
PCR amplification of genomic DNA and DNA sequencing
The GH 1 genes of an affected child from the IGHDII family (Fig. 1,  arrow) were PCR amplified using forward and reverse oligonucleotide primers corresponding to nucleotides 4556 -4575 (5Ј-CCAGCAATGCT-CAGGGAAAG-3Ј) and the complement of 7255-7226 (5Ј-TGTCCCAC-CGGTTGGGCATGGCAGGTAGCC-3Ј) of the GH gene cluster, respectively (16) . PCR mixtures were denatured for 2 min at 92 C and cycled 35 times (92 C for 1 min; 63 C for 45 sec; 68 C for 3 min). The resulting PCR products containing GH 1 sequences (2700 bp) were cleaned by filtration with a Microcon-50 microconcentrator (Amicon, Danvers, MA) and used as templates for direct sequencing. Sequencing was performed by the dideoxy method (17) using the Thermo Sequenase Cycle Sequencing Kit (Amersham Pharmacia Biotech, Piscataway, NJ), and the results are shown in Fig. 2 .
Site-directed mutagenesis, in vitro expression studies, and RNA purification
Human GH expression vectors containing mutations were constructed using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) and mutant oligonucleotide primers (see Table 2 ). After confirming that the desired mutation was present, fragments containing GH 1 
Synthesis and quantitative RT-PCR of GH cDNA
First-strand GH 1 cDNA was synthesized from total RNA using the SuperScript Preamplification System (Life Technologies, Inc.) and the GH 1 -specific reverse primer 5Ј-ACAAGGCTGGTGGGCACTGGAGT-3Ј, corresponding to the complement of 6775-6753 of the GH gene cluster. The first-strand cDNA products were cleaned by filtration with a Microcon 50 microconcentrator (Amicon), then used as templates for 25-l PCRs for cycle curves and quantitative PCR analysis (18) . 5Ј-Endlabeled GH 1 -specific forward primer (5Ј-CGTCTGCACCAGCTGGC-CTTT-3Ј) and reverse primer (5Ј-CCACAGCTGCCCTCCACAGA-3Ј) corresponding to 5563-5583 and the complement of 6686 -6667 of the GH gene cluster, respectively, were used to amplify GH 1 cDNAs. To determine the optimal cycle number at which cDNAs of different lengths were amplified exponentially, GH 1 cDNAs from two independent transfections with wild-type pXGH5 constructs were amplified in PCR mixtures denatured for 10 min at 95 C and cycled 22-32 times (94 C for 45 sec, 72 C for 30 sec, 72 C for 2 min). Cycle curves were plotted, and it was determined that the linear range of PCR amplification was 23-25 cycles for all products. Thus, 25 l quantitative PCRs using the cDNA products from transfections with wild-type or mutant pXGH5 constructs were performed for 23 or 24 cycles following the above-mentioned cycling conditions. The RT-PCR products were separated on 5% nondenaturing polyacrylamide gels that were dried following electrophoresis and exposed to a phosphorimager screen for 24 h. The relative amounts of full-length, cryptic, and E3-skipped cDNA amplicons were quantitated with a PhosphorImager and ImageQuant software (Molecular Dynamics, Inc., Sunnyvale, CA). 
Results

Sequencing of GH 1 alleles
The sequences of the GH 1 alleles of an affected child from our IGHD II family were determined by direct sequencing of PCR products (Fig. 2) . The sequencing ladders represent the corresponding nucleotide sequences derived from normal (Fig. 2, left) and patient (Fig. 2, right) DNAs. Note that the patient is heterozygous for an A3 G transition at the fifth base of E3 (E3ϩ 5 A3 G). Also note that this base is part of a GAAGAA ESE motif that immediately follows the 3Ј splice site of IVS2 (Fig. 2B) .
Restriction endonuclease detection
The E3ϩ 5 A3 G mutation was found to destroy an MboII restriction endonuclease site that was used to demonstrate heterozygosity for the mutation in all affected family members (Fig. 3) . Digestion of the 2700-bp PCR products from normal subjects with MboII generated eight fragments: the 1322-, 371-, 363-, and 266-bp fragments shown in Fig. 3 and the 211-, 115-, 45-, and 7-bp fragments (data not shown). The presence of the E3ϩ 5 A3 G transition destroyed an MboII site and, as a result, yielded an abnormal 1588-bp fragment instead of the normal 1322-and 266-bp fragments (Fig. 3) . The presence of the 1588-bp as well as the 1322-and 266-bp fragments in the digested PCR products of affected family members (Fig. 3, lanes 2 and 5-8 ) demonstrates that they are heterozygous for the E3ϩ 5 A3 G transition, in agreement with an autosomal dominant mode of inheritance. All of the unaffected family members are homozygous normal (Fig. 3,  lanes 1, 3, and 9 ).
Analysis of transcripts of GH 1 alleles
To determine the effects of the A3 G transition on GH mRNA splicing, expression constructs containing the normal GH 1 gene (E3ϩ 5A) or the E3ϩ 5 A3 G mutant allele were transfected into GH 3 cells, and the GH transcripts were analyzed by DNA sequencing of quantitative RT-PCR products (18) . The normal GH 1 gene yielded normally spliced GH transcripts (Fig. 4, lane 1) , whereas the ϩ5 A3 G allele yielded an increased proportion of transcripts whose E3 was either partially or completely skipped, causing the loss of amino acids 32-46 or 32-71, respectively (Fig. 4, lane 2, 368   FIG. 2 . Identification of mutation in exon 3 of IGHD II individual. A, Comparison of DNA sequencing ladders of IGHD II subject IV-1 and a normal control derived from direct sequencing of PCR-amplified GH genes. Heterozygosity for the exon 3 ϩ5 A3 G substitution is indicated by the bold A/G. The intron 2/exon 3 junction is indicated by a dash. B, Diagram of GH 1 gene region where the ϩ5 A3 G mutation is located, showing 5Ј, 3Ј, and cryptic 3Ј splice sites. Bases ϩ1, ϩ5, and ϩ45 of E3 are labeled to indicate the first base of E3, the A3 G mutation, and the ϩ45 cryptic 3Ј splice site, respectively. The ESE is shown in uppercase letters.
and 293 bp, respectively). To determine the effects of other ESE base changes on GH mRNA splicing, expression constructs containing point mutations at the second, third, fourth, or sixth position in the ESE motif were transfected into GH 3 cells, and the quantitative RT-PCR products were analyzed. Each mutant GH 1 allele yielded an increased percentage of transcripts with partial or complete skipping of E3 (Fig. 4, lanes 3-8) .
Discussion
The E3ϩ 5 A3 G transition was only found in affected individuals in our IGHD II family. All family members with IGHD II were determined to be heterozygous for the mutation, in agreement with an autosomal dominant mode of inheritance. The E3ϩ 5 A3 G mutation was not detected in 49 CEPH controls (98 chromosomes) or in 26 samples (52 chromosomes) from other IGHD subjects.
The E3ϩ 5 A3 G transition is a missense mutation that encodes a glutamate (GAA) to glycine (GGA) substitution at codon 33 (E33G). It is possible that this amino acid substitution may affect the secondary structure of the GH protein due to a change from the bulky, acidic, polar side-chain in glutamate to the smaller, nonpolar side-chain in glycine. However, it is unlikely that this substitution would affect binding to GH receptor, because amino acid 33 does not appear to be a part of the GH receptor-binding site (19) . Interestingly, the E3ϩ 5 A3 G transition is located within a GAAGAA ESE motif (13) immediately following the IVS2 3Ј splice site. Pre-mRNA splicing enhancer elements are capable of activating weak splice sites in nearby introns (20) . It is not surprising, therefore, to discover this ESE, since the IVS2 3Ј splice site was known to be weak compared with other downstream acceptor splice sites (21) . We hypothesize that under normal conditions, this ESE promotes activation of the IVS2 3Ј splice site and, in turn, production of the normal 22-kDa GH protein.
To determine the mechanism by which the E3ϩ 5 A3 G transition in the ESE motif causes IGHD II, expression constructs containing the normal GH 1 gene or the mutant allele were transfected into GH 3 cells. The resulting GH transcripts were analyzed by DNA sequencing of RT-PCR products. Some transcripts of constructs containing the ϩ5 A3 G ESE mutation exhibited aberrant splicing, with activation of an E3ϩ 45 cryptic 3Ј splice site, resulting in deletion of the first 15 nucleotides of E3 and loss of amino acids 32-46, corresponding to the 20-kDa isoform of GH (6) . Other mutant transcripts arose by aberrant splicing that resulted in skipping of E3 and loss of the codons for amino acids 32-71, which correspond to the 17.5-kDa isoform of GH (6) . The deficiency of GH and the GHD phenotype of individuals heterozygous for the E3ϩ 5 A3 G mutation suggest the dominant negative mechanism reported previously for an IVS3 ϩ6 T3 C transition (4) .
Analysis of RT-PCR products showed that approximately 62% of mutant transcripts exhibiting aberrant splicing lack E3 completely. It is unclear why, in the presence the E3ϩ 5 A3 G mutation that disrupts an ESE motif, E3 skipping is favored over use of the E3ϩ 45 cryptic splice site, which is the next available 3Ј splice site following the weak IVS2 3Ј splice site. It is possible that other elements, such as silencers, act, in addition to the E3 ESE we have detected, to prevent utilization of the E3ϩ 45 cryptic site in favor of activation of the IVS3 3Ј splice site, which results in large amounts of 17.5-kDa isoforms.
To determine the effects of other ESE base changes on GH 1 pre-mRNA splicing, expression constructs containing single base ESE mutations were transfected into GH 3 cells, and the resulting GH transcripts were analyzed by DNA sequencing of the RT-PCR products. Importantly, all mutant alleles, including two that have no effect on ESE purine content or the encoded amino acid (GAAGAA3 GAGGAA and GAAGAA3 GAAGAG), exhibited aberrant splicing similar to that of the ϩ5A3 G transition. Thus, altering any base within this ESE motif disrupts the function of the ESE, resulting in aberrant splicing.
In conclusion, our data show that GH 1 alleles with a ϩ5 A3 G transition in E3 cause IGHD II by perturbing GH pre-mRNA splicing due to the disruption of an ESE. It has been estimated that 15% of point mutations resulting in human genetic diseases cause splicing defects (22) , and many of these mutations affect a sequence that resembles an ESE (23) . Thus, we provide here an example of an ESE mutation that causes a human genetic disease by deranging alternative splicing (23) (24) (25) (26) . Our finding that translationally silent point mutations (GAAGAA3 GAGGAA or GAAGAA3 GAAG-AG) can affect splicing by perturbing ESEs shows that analogous changes in other genes may also derange splicing. Thus, single base substitutions that cause disease should be more carefully evaluated by studying their potential effects on pre-mRNA splicing. 
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